News Headline Summary

Analysis confirms Johnson and Johnson's (JNJ) Janssen unit's Xarelto has similar efficacy and reduces the incidence of major bleeding by nearly half compared to standard of care in treatment of DVT and PE

Print 12:49, 20 Sep 2013 - US Equities - Source: Newswires